Why the Orthocell share price is up more than 200% today

The Orthocell Ltd (ASX: OCC) share price has rocketed over 200% higher today after an ASX update from the Aussie regenerative medicine company.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price has rocketed over 200% higher today after an ASX update on its nerve regeneration trial.

What did Orthocell announce?

The regenerative medicine company announced that the first four patients have successfully completed participation in its CelGro nerve regeneration clinical trial.

Following surgery with CelGro, these patients regained muscle function and/or sensation of affected limbs and have returned to work, sport and activities of daily living.

Management said the trial is being undertaken with leading Western Australian orthopaedic nerve specialist, Dr Alex O'Beirne of St John of God Subiaco Hospital and Professor Ming Hao Zheng of the University of Western Australia.

The company said that patients experienced an 83% improvement in muscle power with initial results indicating that CelGro can be used to guide and support nerve regeneration in severely damaged or severed peripheral nerves of the hand and upper limbs.

Orthocell said that patient treatment is 75% complete (15 out of 20 patients) with recruitment expected to be completed before the end of June 2019.

Why has the share price soared higher?

Today's results are a big breakthrough for the Aussie medical group with indications that CelGro can accelerate and augment the repair of damaged or severed nerves.

Managing Director Paul Anderson said that the early results are an important step forward in the development of the CelGro platform in the area of human nerve regeneration.

According to this morning's release, over 20 million people in just the United States suffer from peripheral nerve injury as a result of motor vehicle, sporting or work-related incidents every year, with an annual cost of US$150 billion per annum.

Management estimates CelGro's addressable market in peripheral nerve repair at US$1.1 billion per annum, with approximately 700,000 procedures that could use CelGro being completed every year.

For those who want to find the next hot growth company, this top-rated stock could boost portfolio gains as it continues to soar in a $22 billion industry.

Motley Fool contributor Lachlan Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »